TY - JOUR
T1 - Association between impaired glucose metabolism and quality of life
T2 - Results from the Australian diabetes obesity and lifestyle study
AU - Tapp, Robyn J.
AU - Dunstan, David W.
AU - Phillips, Pat
AU - Tonkin, Andrew
AU - Zimmet, Paul Z.
AU - Shaw, Jonathan E.
N1 - Funding Information:
We are most grateful to the following for their support of the study: the Commonwealth Department of Health and Aged Care, Abbott Australasia Pty Ltd., Alphapharm Pty Ltd., Aventis Pharmaceutical, AstraZeneca, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Aust) Pty Ltd., GlaxoSmithKline, Janssen-Cilag (Aust) Pty Ltd., Merck Lipha s.a., Merck Sharp & Dohme (Aust), Novartis Pharmaceutical (Aust) Pty Ltd., Novo Nordisk Pharmaceutical Pty Ltd., Pharmacia and Upjohn Pty Ltd., Pfizer Pty Ltd., Roche Diagnostics, Sanofi Synthelabo (Aust) Pty Ltd., Servier Laboratories (Aust) Pty Ltd., BioRad Laboratories Pty Ltd., HITECH Pathology Pty Ltd., the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services, Victorian Department of Human Services and Health Department of Western Australia. Also, for their invaluable contribution to the set-up and field activities of AusDiab, we are enormously grateful to A. Allman, B. Atkins, S. Bennett, S. Chadban, S. Colagiuri, M. de Courten, M. Dalton, M. D’Embden, T. Dwyer, D. Jolley, I. Kemp, P. Magnus, J. Mathews, D. McCarty, A. Meehan, K. O’Dea, P. Phillips, P. Popplewell, C. Reid, A. Stewart, R. Tapp, H. Taylor, T. Welborn and F. Wilson. R.J. Tapp is supported by scholarships from the National Health and Medical Research Council of Australia (grant number 284460) and the Victorian Health Promotion Foundation (grant number 2003-0748).
PY - 2006/11
Y1 - 2006/11
N2 - Aims: We examined the association of quality of life with glucose tolerance status in an Australian population to determine the stage in the development of diabetes that quality of life is impaired. Methods: The Australian Diabetes, Obesity and Lifestyle study (AusDiab) was a population-based study of 11,247 people from randomly selected areas of Australia. As part of the study, participants underwent an oral glucose tolerance test and completed the SF-36 quality of life questionnaire. Results: Previously diagnosed diabetes was associated with a significantly greater risk of being in the lowest quartile of each dimension of the SF-36 scale (except for mental health) and this association was only partially attenuated by adjustment for age, sex, body mass index (BMI), physical activity and treatment for hypertension and lipid abnormalities (adjusted odds ratios [95% CI]: bodily pain, 1.51 [1.18-1.94]; general health, 2.20 [1.64-2.95]; physical functioning, 1.50 [1.10-2.05]; role limitation (emotional), 1.43 [1.07-1.91]; role limitation (physical), 1.57 [1.13-2.18]; social functioning, 1.93 [1.46-2.54] and vitality, 2.24 [1.56-3.22]. Among those with newly diagnosed diabetes (NDM) and impaired glucose tolerance (IGT), there was also evidence of reduced quality of life on some dimensions of the SF-36 scale (NDM, general health, physical functioning and role limitation (physical); IGT, physical functioning and social functioning) after adjustment for confounders. Conclusion: These findings show that diabetes is associated with a reduced quality of life and that this is evident in the early stage of the disease, particularly in relation to the ability to perform physical activities.
AB - Aims: We examined the association of quality of life with glucose tolerance status in an Australian population to determine the stage in the development of diabetes that quality of life is impaired. Methods: The Australian Diabetes, Obesity and Lifestyle study (AusDiab) was a population-based study of 11,247 people from randomly selected areas of Australia. As part of the study, participants underwent an oral glucose tolerance test and completed the SF-36 quality of life questionnaire. Results: Previously diagnosed diabetes was associated with a significantly greater risk of being in the lowest quartile of each dimension of the SF-36 scale (except for mental health) and this association was only partially attenuated by adjustment for age, sex, body mass index (BMI), physical activity and treatment for hypertension and lipid abnormalities (adjusted odds ratios [95% CI]: bodily pain, 1.51 [1.18-1.94]; general health, 2.20 [1.64-2.95]; physical functioning, 1.50 [1.10-2.05]; role limitation (emotional), 1.43 [1.07-1.91]; role limitation (physical), 1.57 [1.13-2.18]; social functioning, 1.93 [1.46-2.54] and vitality, 2.24 [1.56-3.22]. Among those with newly diagnosed diabetes (NDM) and impaired glucose tolerance (IGT), there was also evidence of reduced quality of life on some dimensions of the SF-36 scale (NDM, general health, physical functioning and role limitation (physical); IGT, physical functioning and social functioning) after adjustment for confounders. Conclusion: These findings show that diabetes is associated with a reduced quality of life and that this is evident in the early stage of the disease, particularly in relation to the ability to perform physical activities.
KW - Complications
KW - Diabetes mellitus
KW - Glucose tolerance status
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=33751076857&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2006.03.012
DO - 10.1016/j.diabres.2006.03.012
M3 - Article
C2 - 16740334
AN - SCOPUS:33751076857
SN - 0168-8227
VL - 74
SP - 154
EP - 161
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
IS - 2
ER -